BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20041717)

  • 21. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
    Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
    Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.
    Chartier A; Raz V; Sterrenburg E; Verrips CT; van der Maarel SM; Simonelig M
    Hum Mol Genet; 2009 May; 18(10):1849-59. PubMed ID: 19258344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice.
    Dion P; Shanmugam V; Gaspar C; Messaed C; Meijer I; Toulouse A; Laganiere J; Roussel J; Rochefort D; Laganiere S; Allen C; Karpati G; Bouchard JP; Brais B; Rouleau GA
    Neurobiol Dis; 2005 Apr; 18(3):528-36. PubMed ID: 15755680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
    Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
    J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
    Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
    J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability of the recessive oculopharyngeal muscular dystrophy phenotype.
    Semmler A; Kress W; Vielhaber S; Schröder R; Kornblum C
    Muscle Nerve; 2007 May; 35(5):681-4. PubMed ID: 17206657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells.
    Kalle AM; Mallika A; Badiger J; Alinakhi ; Talukdar P; Sachchidanand
    Biochem Biophys Res Commun; 2010 Oct; 401(1):13-9. PubMed ID: 20813094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.
    Abu-Baker A; Parker A; Ramalingam S; Laganiere J; Brais B; Neri C; Dion P; Rouleau G
    Neurology; 2018 Aug; 91(6):e551-e561. PubMed ID: 30006409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ectopic expression of a polyalanine expansion mutant of poly(A)-binding protein N1 in muscle cells in culture inhibits myogenesis.
    Wang Q; Bag J
    Biochem Biophys Res Commun; 2006 Feb; 340(3):815-22. PubMed ID: 16378590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
    Huber K; Schemies J; Uciechowska U; Wagner JM; Rumpf T; Lewrick F; Süss R; Sippl W; Jung M; Bracher F
    J Med Chem; 2010 Feb; 53(3):1383-6. PubMed ID: 20030343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
    Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
    Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy.
    Raz V; Sterrenburg E; Routledge S; Venema A; van der Sluijs BM; Trollet C; Dickson G; van Engelen BG; van der Maarel SM; Antoniou MN
    BMC Neurol; 2013 Jul; 13():70. PubMed ID: 23815790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of expression and co-localization of heat shock polypeptides with the polyalanine expansion mutant of poly(A)-binding protein N1 after chemical stress.
    Wang Q; Bag J
    Biochem Biophys Res Commun; 2008 May; 370(1):11-5. PubMed ID: 18343218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirtuin Inhibition Adversely Affects Porcine Oocyte Meiosis.
    Zhang L; Ma R; Hu J; Ding X; Xu Y
    PLoS One; 2015; 10(7):e0132941. PubMed ID: 26176547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
    van der Sluijs BM; van Engelen BG; Hoefsloot LH
    Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
    Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging.
    Anvar SY; Raz Y; Verway N; van der Sluijs B; Venema A; Goeman JJ; Vissing J; van der Maarel SM; 't Hoen PA; van Engelen BG; Raz V
    Aging (Albany NY); 2013 Jun; 5(6):412-26. PubMed ID: 23793615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.
    Vergnes B; Vanhille L; Ouaissi A; Sereno D
    Acta Trop; 2005 May; 94(2):107-15. PubMed ID: 15860278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.